The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood

Pediatric Nephrology

Volumn 27, Issue 2, 2012, Pages 269-275

  Giannini, Cosimo ^a   D'Adamo, Ebe ^a   De Giorgis, Tommaso ^a   Chiavaroli, Valentina ^a   Verrotti, Alberto ^a   Chiarelli, Francesco ^a   Mohn, Angelika ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

AGE; Diabetic nephropathy; EsRAGE; SRAGE; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

BODY SURFACE; CHILD; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SCHOOL CHILD;

CHILD; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS;

EID: 84857110077     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-011-1988-5     Document Type: Review

References (37)

1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T (2005) Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 28:164-176 (Pubitemid 40095801)
2. Bogdanovic R (2008) Diabetic nephropathy in children and adolescents. Pediatr Nephrol 23:507-525 (Pubitemid 351356455)
3. Thomson SC, Vallon V, Blantz RC (2004) Kidney function in early diabetes: The tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 286:F8-F15 (Pubitemid 38045037)
4. Bak M, Thomsen K, Christiansen T, Flyvbjerg A (2000) Renal enlargement precedes renal hyperfiltration in early experimental diabetes in rats. J Am Soc Nephrol 11:1287-1292 (Pubitemid 30416225)
5. Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, Vallon V (2001) Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 107:217-224 (Pubitemid 32096838)
6. Wolf G, Ziyadeh FN (1999) Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56:393-405 (Pubitemid 29353136)
7. Ohta Y, Fujii K, Arima H, Matsumura K, Tsuchihashi T, Tokumoto M, Tsuruya K, Kanai H, Iwase M, Hirakata H, Iida M (2005) Increased renal resistive index in atherosclerosis and diabetic nephropathy assessed by Doppler sonography. J Hypertens 23:1905-1911 (Pubitemid 41830431)
8. Frauchiger B, Nussbaumer P, Hugentobler M, Staub D (2000) Duplex sonographic registration of age and diabetes-related loss of renal vasodilatory response to nitroglycerine. Nephrol Dial Transplant 15:827-832 (Pubitemid 30312001)
9. Platt JF, Rubin JM, Ellis JH (1994) Diabetic nephropathy: Evaluation with renal duplex Doppler US. Radiology 190:343-346 (Pubitemid 24044231)
10. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820 (Pubitemid 34000785)
11. Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52:2251-2263
12. Sakurai S, Yonekura H, Yamamoto Y, Watanabe T, Tanaka N, Li H, Rahman AK, Myint KM, Kim CH, Yamamoto H (2003) The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 14:S259-S263 (Pubitemid 36903937)
13. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097-1109 (Pubitemid 36399105)
14. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa Y (2006) Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 55:2245-2255 (Pubitemid 44743621)
15. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031 (Pubitemid 28417334)
16. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827-2835 (Pubitemid 35396983)
17. National High Blood Pressure Education ProgramWorking Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576.
18. Rolland-Cachera MF, Cole TJ, Sempe M, Tichet J, Rossignol C, Charraud A (1991) Body Mass Index variations: Centiles from birth to 87 years. Eur J Clin Nutr 45:13-21
19. Savino A, Pelliccia P, Giannini C, de Giorgis T, Cataldo I, Chiarelli F, Mohn A (2011) Implications for kidney disease in obese children and adolescents. Pediatr Nephrol 26:749-758
20. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS (2003) National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: Evaluation, classification, and stratification. Pediatrics 111:1416-1421 (Pubitemid 36682280)
21. Bakker J, Olree M, Kaatee R, de Lange EE, Moons KG, Beutler JJ, Beek FJ (1999) Renal volume measurements: Accuracy and repeatability of US compared with that of MR imaging. Radiology 211:623-628 (Pubitemid 29249454)
22. Konus OL, Ozdemir A, Akkaya A, Erbas G, Celik H, Isik S (1998) Normal liver, spleen, and kidney dimensions in neonates, infants, and children: Evaluation with sonography. AJR Am J Roentgenol 171:1693-1698 (Pubitemid 28531650)
23. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25:2587-2593 (Pubitemid 43732283)
24. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, Scioli GA, Fogari R (2005) Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23:1725-1729 (Pubitemid 41233433)
25. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ (2006) Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49:2756-2762
26. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A (2007) Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9
27. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Umayahara Y, Kosugi K, Yamasaki Y (2009) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204:288-292
28. Zerbini G, Bonfanti R, Meschi F, Bognetti E, Paesano PL, Gianolli L, Querques M, Maestroni A, Calori G, Del Maschio A, Fazio F, Luzi L, Chiumello G (2006) Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes 55:2620-2625 (Pubitemid 44871164)
29. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, Ohtoshi K, Hayaishi-Okano R, Kosugi K, Hori M, Yamasaki Y (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: Its possible association with diabetic vascular complications. Diabetes Care 28:2716-2721 (Pubitemid 43951165)
30. Miura J, Yamamoto Y, Osawa M, Watanabe T, Yonekura H, Uchigata Y, Yamamoto H, Iwamoto Y (2007) Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 27:253-254 (Pubitemid 46360409)
31. Marcovecchio ML, Giannini C, Dalton RN, Widmer B, Chiarelli F, Dunger DB (2009) Reduced endogenous secretory receptor for advanced glycation end products (esRAGE) in young people with Type 1 diabetes developing microalbuminuria. Diabet Med 26:815-819
32. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876-886 (Pubitemid 41598688)
33. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation 105:816-822 (Pubitemid 34174921)
34. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117-1128
35. Rossing P (2006) Prediction, progression and prevention of diabetic nephropathy. The Minkowski lecture 2005. Diabetologia 49:11-19 (Pubitemid 43151607)
36. Caramori ML, Fioretto P, Mauer M (2006) Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 17:339-352
37. Dahlquist G, Stattin EL, Rudberg S (2001) Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transplant 16:1382-1386 (Pubitemid 32640592)